1. Home
  2. MTLS vs LUNG Comparison

MTLS vs LUNG Comparison

Compare MTLS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Materialise NV

MTLS

Materialise NV

SELL

Current Price

$8.12

Market Cap

431.6M

Sector

Technology

ML Signal

SELL

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

SELL

Current Price

$1.85

Market Cap

97.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MTLS
LUNG
Founded
1990
1995
Country
Belgium
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Industrial Specialties
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
431.6M
97.1M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
MTLS
LUNG
Price
$8.12
$1.85
Analyst Decision
Buy
Buy
Analyst Count
3
5
Target Price
★ $8.76
$3.40
AVG Volume (30 Days)
213.0K
★ 261.6K
Earning Date
10-28-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.64
EPS
★ N/A
N/A
Revenue
N/A
★ $90,497,000.00
Revenue This Year
$3.97
$0.06
Revenue Next Year
$5.95
$8.58
P/E Ratio
$61.39
★ N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$4.78
$1.13
52 Week High
$8.82
$2.89

Technical Indicators

Market Signals
Indicator
MTLS
LUNG
Relative Strength Index (RSI) 53.57 47.11
Support Level $6.37 $1.20
Resistance Level $8.82 $2.12
Average True Range (ATR) 0.21 0.11
MACD -0.09 -0.00
Stochastic Oscillator 13.92 51.79

Price Performance

Historical Comparison
MTLS
LUNG

About MTLS Materialise NV

Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: